Improving thymus implantation for congenital athymia with interleukin‐7

OBJECTIVES: Thymus implantation is a recently FDA‐approved therapy for congenital athymia. Patients receiving thymus implantation develop a functional but incomplete T cell compartment. Our objective was to develop a mouse model to study clinical thymus implantation in congenital athymia and to opti...

Descripción completa

Detalles Bibliográficos
Autores principales: Min, Hyunjung, Valente, Laura A, Xu, Li, O'Neil, Shane M, Begg, Lauren R, Kurtzberg, Joanne, Filiano, Anthony J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665642/
https://www.ncbi.nlm.nih.gov/pubmed/38020730
http://dx.doi.org/10.1002/cti2.1475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665642/
https://www.ncbi.nlm.nih.gov/pubmed/38020730
http://dx.doi.org/10.1002/cti2.1475

Ejemplares similares